United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

General Motors

A busy earnings week includes GM, Pfizer results as well as the upcoming trial for disgraced former Theranos CEO Elizabeth Holmes.

Pfizer, GM earnings and jobs report top week ahead

Moderna

BioNTech SE

Both vaccines do an impressive job of providing protection against COVID-19. But Moderna's is much easier to get from production facilities into patients' arms.

Moderna Just Made the Pfizer Vaccine's Biggest Weakness an Even Bigger One

Pfizer is moving beyond coronavirus prevention.

The Pfizer CEO Prediction That Could Mean Total COVID Market Dominance in 2022

The two companies stand an excellent chance of winning expanded authorization in Europe for their coronavirus vaccine.

Why Pfizer and BioNTech Shot Higher on Friday

The protection from the first dose is “significantly enhanced” if someone has already had Covid.

Single Pfizer Vaccine Shot May Not Protect Against Covid Variants, Study Warns

According to a U.K. study, a single dose of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19, reports Reuters. The Imperial College-led study, which analyzed blood samples among healthcare workers after their first dose of the Pfizer shot, found that those who previously had the infection showed better protection against virus variants found in Britain and South Africa.

Two Doses Pfizer-BioNTech COVID-19 Vaccine Necessary To Generate Immune Response Against Variants, UK Study Show: Reuters

2 Doses Pfizer-BioNTech COVID-19 Vaccine Necessary To Generate Immune Response Against Variants, UK Study Show: Reuters

CVS Health

Under Armour

Ballard Power Systems

SolarEdge Technologies

More than 900 publicly traded companies are scheduled to report March quarter earnings next week, with heavy representation from energy exploration and production companies.

Earnings Previews: CVS, Pfizer, Under Armour and More

Novartis

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during the first quarter of 2021, which ended on March 31.

The Eaton Vance Fund sells Novartis, Pfizer

Pfizer and BioNTech have asked for authorization from the European Medicines Agency to use their COVID-19 vaccines in kids ages 12-15. Children in the European Union might be eligible to roll up their sleeves soon.

Pfizer and BioNTech want to vaccinate European kids ages 12-15

The companies have already asked the FDA to expand its license to cover some children in the U.S..

Pfizer, BioNTech Seek Approval To Extend Covid-19 Vaccine For Use Among Teenagers

BioNTech and Pfizer seek European OK to use COVID vaccine in kids as young as 12

Intuitive Surgical

Teladoc

Don't wait to snag these three golden eggs for your basket of stocks.

3 Healthcare Stocks That Could Be Millionaire-Makers

Pfizer Inc. (NYSE: PFE) has started exporting COVID-19 vaccine doses produced in its U.S. plant to Mexico, Reuters reported Thursday, citing a person familiar with the matter. What Happened: The shipment of vaccine doses from Pfizer's Kalamazoo, Michigan plant to Mexico is the first export from the U.S. by the drugmaker after a restriction on dose exports by the former President Donald Trump's administration expired at the end of March, as per the Reuters report.

Pfizer Said To Have Begun Exporting US-Made COVID-19 Vaccine

Loncar China Biopharma ETF

Loncar Cancer Immunotherapy ETF

CRISPR Therapeutics

CureVac B.V

Editas Medicine

iShares Nasdaq Biotechnology ETF

Telesis Bio Inc

SPDR S&P Biotech ETF

Here is what you should know about investing in these life changing technologies.

Best Biotech Stocks & ETFs for mRNA, Gene Editing

BioNTech SE's (NASDAQ: BNTX) CEO Ugur Sahin says the company, along with its partner Pfizer Inc (NYSE: PFE), could have data from trials testing the COVID-19 vaccine in babies as young as six months old by September, according to Reuters.  "In July, the first results could be available for the five to 12-year-olds, in September for the younger children," BioNTech Chief Executive Ugur Sahin told the German magazine, Der Spiegel, per Reuters.

Pfizer-BioNTech Bullish On COVID-19 Vaccine Trial Results In Infants By September: Reuters

Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the first quarter.

Will Pfizer (PFE) Deliver a Beat This Earnings Season?

BioNTech submitting applications in US and Europe for vaccine to be available to those aged 12-15

Pfizer/BioNTech Covid jab may be offered to 12-year-olds in Europe from June

AbbVie

Amgen

Bristol-Myers

Johnson & Johnson

SoFi Select 500 ETF

High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now.

7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends

Unilever

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Verizon stays on my dividend stock watch list for another month! The 5G auction ended with over $80 Billion and Verizon, of course, led the charge. Unilever has had their stock price drop to $56.88 from $60.53 on January 4th 2021. In fact, that represents a 6% drop year-to-date.

Dividend Stock Watch List: Lanny's May 2021 Edition

Pfizer Inc. (NYSE: PFE) has acquired Amplyx Pharmaceuticals Inc., a privately-held company focused on developing therapies for people with compromised immune systems who face debilitating and life-threatening diseases. Focus on Amplyx: Founded in 2006 and headquartered in San Diego, Amplyx lead drug is Fosmanogepix, a novel investigational asset under development for the treatment of invasive fungal infections, of which there are more than 1.5 million cases worldwide each year, with mortality rates ranging as high as 80%.

Pfizer Acquires Amplyx Pharmaceuticals: What You Need To Know

The two-dose vaccines were also found to be 64% effective at preventing hospitalizations in the elderly who received just one shot, according to the CDC study.

Pfizer, Moderna vaccines 94% effective at preventing hospitalizations in elderly, CDC study shows

Adults of 65 years and older are 94% less likely to be hospitalized with COVID-19 if they have been fully vaccinated with either of the two mRNA vaccines that have received emergency use authorization in the U.S., compared with people of the same age who are not vaccinated, the Centers for Disease Control and Prevention said Wednesday. People who are partially vaccinated with those vaccines -- one developed by Pfizer Inc. and German partner BioNTech SE , and one developed by Moderna Inc. -- are 64% less likely to be hospitalized compared with people who are not vaccinated, the agency said.

Older adults 94% less likely to be hospitalized with COVID after receiving Pfizer or Moderna vaccines: CDC

Crocs

Skechers U.S.A.

Retail stocks have been rockin' – especially for shoemakers. Here are three sizzling stocks to buy with the wind at their backs.

3 Shoe Stocks to Buy as They Run Higher

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx's lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. More than 1.5 million cases of invasive fungal infections occur worl

News for Pfizer Stock (PFE)